{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:25:10Z","timestamp":1789057510590,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Fisabio-DS-CST Promoter Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Leishmaniasis is an emerging opportunistic infection in patients with inflammatory bowel disease (IBD) living in Mediterranean endemic areas. However, the magnitude of the risk and treatment-related determinants remain unknown, and no controlled population-based studies have addressed this issue. We aimed to estimate the incidence of symptomatic Leishmania infection in IBD population and to identify associated clinical and therapeutic risk factors, particularly immunosuppressive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An observational study was conducted in the Valencian Community (Spain) between 2015 and 2022, involving 16 hospitals. The study comprised 3 components: (1) a population-based retrospective cohort to estimate incidence of leishmaniasis in IBD patients; (2) a multicenter case series, to characterize clinical presentation, diagnosis, and outcomes; and (3) a matched 1:2 case\u2013control study, to identify factors associated with the infection. Cases were adults with Crohn\u2019s disease or ulcerative colitis and confirmed symptomatic Leishmania (polymerase chain reaction [PCR], histology or culture). Controls were matched by sex, IBD subtype, and year of birth (\u00b110\u2009years). Immunosuppressive exposure at the index date was recorded. Conditional logistic regression was used to identify independent predictors of infection, with covariate selection guided by a directed acyclic graph.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-two cases were identified: 80.5% cutaneous, 14.6% visceral, and 4.9% mucocutaneous leishmaniasis. The mean annual incidence was 0.464 per 1000 IBD patients, 13.2-fold higher than in the general population (0.0035 per 1000; P\u2009&amp;lt;\u2009.001). Comorbidities were more frequent among cases. Diagnosis often requires PCR, with\u2009\u2265\u20092 biopsies needed in 26.2% of patients. At infection, 90.1% of cases vs 44.5% of controls were receiving biologic therapy (P\u2009&amp;lt;\u2009.001). Anti-TNF exposure, combination therapy (biologic plus immunomodulator), and escalated biologic regimens were more frequent among cases (P\u2009&amp;lt;\u2009.001). Overall, 90.7% of patients achieved cure with first-line therapy; been systemic treatment reserved for refractory cutaneous disease. Differences were observed between continuation or withdrawal of immunosuppressive therapy along first-line treatment (P-value = .036). In multivariable analysis, biologic therapy (adjusted odds ratio [OR] 16.1; 95% CI, 4.56-57.1) and presence of comorbidities (adjusted OR 6.47; 95% CI, 1.66-25.2) were independently associated with infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the Mediterranean endemic areas, patients with IBD have a markedly increased risk of developing symptomatic leishmaniasis. Biologic therapy represents the principal driver of infection risk, underscoring the need for heightened clinical awareness and update guidance on opportunistic infections in endemic regions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag067","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:08:02Z","timestamp":1777637282000},"source":"Crossref","is-referenced-by-count":1,"title":["Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case\u2013control study"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-9367","authenticated-orcid":false,"given":"Leticia","family":"Gimeno-Pitarch","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Hospital General Universitari de Castell\u00f3 , Castell\u00f3n de la Plana,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Iborra","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Research Group, Health Research Institute La Fe (IIS La Fe). IBD Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Crespo","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Arnau de Vilanova , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sanchis","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital de Sagunto , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosario","family":"Ant\u00f3n","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Cl\u00ednic Universitari de Valencia , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pastor","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Luis Alcany\u00eds de X\u00e1tiva , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Mart\u00ed","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Francesc de Borja de Gandia , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Herreros","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital de la Marina Baixa de la Vila Joiosa , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Virgen de Los Lirios de Alcoi , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ru\u00edz","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Consorcio Hospital General Universitario de Valencia , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Almudena P\u00e9rez","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Doctor Peset de Valencia , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francia Carolina","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario de la Ribera , Alzira, Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Maroto","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital de Manises , Manises, Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Laveda","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario San Juan de Alicante , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Madero","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital General Universitario Doctor Balmis , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Buend\u00eda","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Vega Baja de Orihuela , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-1511","authenticated-orcid":false,"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Research Group, Health Research Institute La Fe (IIS La Fe). IBD Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026060806284008300_jjag067-B1","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"2026060806284008300_jjag067-B2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"2026060806284008300_jjag067-B3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026060806284008300_jjag067-B4","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1590\/S1678-9946202062028","article-title":"A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases","volume":"62","author":"Kurizky","year":"2020","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2026060806284008300_jjag067-B5","doi-asserted-by":"publisher","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","author":"Davis","DOI":"10.1128\/CMR.00035-19"},{"key":"2026060806284008300_jjag067-B6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.semarthrit.2013.01.006","article-title":"Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases)","volume":"43","author":"Guedes-Barbosa","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2026060806284008300_jjag067-B7","doi-asserted-by":"publisher","first-page":"e0007708","DOI":"10.1371\/journal.pntd.0007708","article-title":"Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression","volume":"13","author":"Bosch-Nicolau","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2026060806284008300_jjag067-B8","first-page":"555","article-title":"Epidemiological situation and risk factors of Leishmania infantum in Spain","volume":"86","author":"Su\u00e1rez Rodr\u00edguez","year":"2012","journal-title":"RevEspSalud Publica"},{"key":"2026060806284008300_jjag067-B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13071-020-3901-1","article-title":"Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital","volume":"13","author":"Garrido-Jare\u00f1o","year":"2020","journal-title":"Parasit Vectors"},{"key":"2026060806284008300_jjag067-B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4321\/s2173-92772023000200002","article-title":"Situaci\u00f3n de leishmaniasis en Espa\u00f1a. A\u00f1os 2019, 2020 y 2021","volume":"31","author":"Fern\u00e1ndez Mart\u00ednez","year":"2023","journal-title":"BES"},{"key":"2026060806284008300_jjag067-B11","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.21.25322565","article-title":"T cell dysfunction in cutaneous leishmaniasis at single-cell resolution","author":"Avila","year":"2025"},{"key":"2026060806284008300_jjag067-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-022-04530-4","article-title":"Prevalence of visceral leishmaniasis among people with HIV: a systematic review and meta-analysis","volume":"42","author":"Kantzanou","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"2026060806284008300_jjag067-B13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.4269\/ajtmh.2011.11-0310","article-title":"Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008)","volume":"85","author":"Gil-Prieto","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2026060806284008300_jjag067-B14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3201\/eid2307.151251","article-title":"Environmental factors as key determinants for visceral leishmaniasis in solid organ transplant recipients, Madrid, Spain","volume":"23","author":"Carrasco-Ant\u00f3n","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026060806284008300_jjag067-B15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ad.2021.02.008","article-title":"Cutaneous and mucocutaneous leishmaniasis","volume":"112","author":"Abad\u00edas-Granado","year":"2021","journal-title":"In Actas Dermo-Sifiliograficas"},{"key":"2026060806284008300_jjag067-B16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s11606-024-09194-8","article-title":"Characterization of leishmaniasis in pharmacologically immunosuppressed patients. A retrospective study in the Valencian Community, Spain, 2015-2023","volume":"40","author":"Tortajada","year":"2025","journal-title":"J Gen Intern Med"},{"key":"2026060806284008300_jjag067-B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.gastre.2023.04.002","article-title":"Leishmania infection in patients with inflammatory bowel disease: case series and literature review","volume":"47","author":"Gimeno-Pitarch","year":"2024","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda (English Edition)"},{"key":"2026060806284008300_jjag067-B18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ueg2.12740","article-title":"Leishmaniasis in patients with inflammatory bowel disease: a national multicenter study of GETECCU","volume":"13","author":"Madero-Vel\u00e1zquez","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026060806284008300_jjag067-B19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.actatropica.2017.05.022","article-title":"Atypical presentations of cutaneous leishmaniasis: a systematic review","volume":"172","author":"Meireles","year":"2017","journal-title":"Acta Trop"},{"key":"2026060806284008300_jjag067-B20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/ddg.15007","article-title":"Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-\u03b1 inhibitors","volume":"21","author":"Palacios-Diaz","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026060806284008300_jjag067-B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens10010018","article-title":"Visceral dissemination of mucocutaneous leishmaniasis in a kidney transplant recipient","volume":"10","author":"Marques","year":"2020","journal-title":"Pathogens"},{"key":"2026060806284008300_jjag067-B22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.20344\/amp.19446","article-title":"Complicated cutaneous leishmaniasis in a patient under combined immunosuppression","volume":"36","author":"Carujo","year":"2023","journal-title":"Acta Med Port"},{"key":"2026060806284008300_jjag067-B23","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed10080232","article-title":"The diagnostic utility of PCR in FFPE skin biopsies with inconclusive histopathology for suspected cutaneous leishmaniasis: a pilot study from Colombia","volume":"10","author":"Mantilla","year":"2025","journal-title":"Trop Med Infect Dis"},{"key":"2026060806284008300_jjag067-B24","doi-asserted-by":"publisher","first-page":"1453211","DOI":"10.3389\/fmed.2024.1453211","article-title":"Diagnostic challenges in cutaneous leishmaniasis due to atypical Leishmania infantum: pathologists\u2019 insights from re-emergence zones","volume":"11","author":"Ekemen","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026060806284008300_jjag067-B25","doi-asserted-by":"publisher","first-page":"107845","DOI":"10.1016\/j.actatropica.2025.107845","article-title":"Host-microbiota-parasite crosstalk: gut microbiota dysbiosis exacerbates Leishmania infantum pathogenesis through altered immunity and glycerylphosphatide metabolism","volume":"271","author":"Xiao","year":"2025","journal-title":"Acta Trop"},{"key":"2026060806284008300_jjag067-B26","author":"Ministry of Universal Health and Public Health of the Valencian Government","year":"."},{"key":"2026060806284008300_jjag067-B27","author":"National Institute of Statistics","year":"."},{"key":"2026060806284008300_jjag067-B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026060806284008300_jjag067-B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026060806284008300_jjag067-B30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026060806284008300_jjag067-B31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti- tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2026060806284008300_jjag067-B32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","article-title":"Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections","volume":"30","author":"Schneeweiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060806284008300_jjag067-B33","author":"Community of Madrid","year":"2025"},{"key":"2026060806284008300_jjag067-B34"},{"key":"2026060806284008300_jjag067-B35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1469-0691.2011.03674.x","article-title":"Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe","volume":"18","author":"Zanger","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026060806284008300_jjag067-B36","author":"Bongartz","year":"."},{"key":"2026060806284008300_jjag067-B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026060806284008300_jjag067-B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060806284008300_jjag067-B39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00384-019-03501-0","article-title":"Clinical assessment of risk factors for infection in inflammatory bowel disease patients","volume":"35","author":"Tosca","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"2026060806284008300_jjag067-B40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00535-012-0686-9","article-title":"A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"48","author":"Naganuma","year":"2013","journal-title":"J Gastroenterol"},{"key":"2026060806284008300_jjag067-B41","year":"."},{"key":"2026060806284008300_jjag067-B42"},{"key":"2026060806284008300_jjag067-B43","doi-asserted-by":"publisher","first-page":"1717863","DOI":"10.3389\/fcimb.2025.1717863","article-title":"Efficacy and safety of different drugs for the treatment of leishmaniasis: a systematic review and network meta-analysis","volume":"15","author":"Fan","year":"2025","journal-title":"Front Cell Infect Microbiol."},{"key":"2026060806284008300_jjag067-B44","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag067\/68487363\/jjag067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag067\/68487363\/jjag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:28:53Z","timestamp":1780914533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag067\/8703683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag067","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"jjag067"}}